phase II trial

If phase I asks whether a drug is tolerable, phase II asks the harder commercial and scientific question: does it actually help patients who have the disease? This is the stage where a molecule first gets a serious chance to show a benefit, in the people it is meant to treat, at doses that might really be used.

Phase II studies enroll a few dozen to a few hundred patients with the target condition. They look for early signs of efficacy — a tumor shrinking, blood pressure falling, a symptom score improving — while continuing to watch safety, now in sick people whose biology differs from healthy volunteers. A central goal is dose finding: comparing several doses to learn which gives a worthwhile effect with acceptable side effects, often the first real test of the drug's therapeutic window in patients. Many phase II studies are randomized and use a placebo or comparator to keep the read-out honest.

Phase II is famously where the most candidates die. The disease may not respond, the effect may be too small, or the dose that works may also cause unacceptable harm. This is sometimes called the valley of death of drug development, because a promising compound that looked fine in phase I so often stumbles here when asked to prove genuine benefit.